ANSHUL MAHESHWARI

Anshul Maheshwari is a specialist in the healthcare and life sciences industries with experience spanning pre-clinical start-ups to top 10 global life sciences companies. With over 15 years of experience, he has a deep understanding of the evolving healthcare landscape and the life sciences value chain from research and development through to commercialization.

His background comprises of working on biomedical start-ups, consulting for medical device and pharma companies and leading the innovation strategy for medical aesthetics. His wide functional expertise includes strategic planning, business development, commercial operations, business transformation and product commercialization.

Anshul co-founded the pioneering Balanced Skin Dermatology and Aesthetics medical office in Newport Beach and co-leads an advisory and collaborative practice in health, beauty and wellness with his wife and partner, Dr. Tia Paul. He is passionate about empowering medical professionals to pursue entrepreneurship and has helped several physicians in starting their own enterprise.

EDUCATION

2008 – 2009
Cornell University | Ithaca, NY
Master's in Biomedical Engineering (Bio-instrumentation & Innovation Management)

2004 – 2008
Illinois Institute of Technology | Chicago, IL
Bachelor's in Biomedical Engineering | Ed Kaplan Entrepreneur Fellowship

EXPERIENCE

Balanced Skin Dermatology and Aesthetics
2024 - 2025
Managing Partner
Responsible for administrative and managerial activities including industry joint-ventures, marketing and branding, technology acquisition and people management, along with growth and scaling of the medical practice.

Allergan Aesthetics, Abbvie
2022 - 2025
Director of Innovation Strategy
Defined and led programs in medical aesthetics to capture value from emerging market dynamics and upcoming technologies such as GLP-1 medical weight loss, AI visualization, new business models and energy-based modalities.

Gilead Sciences
2021 - 2022
Chief Commercial Officer, Chief of Staff Team
Led organization-wide operational efficiencies projects including promotional review process improvement, supplier selection and engagement, customer engagement and talent development projects as part of the CCO's efficiency objectives

Ernst & Young
2017 – 2021
Director, Life Sciences Strategy
Managed pipeline of life sciences projects with global pharma and medical device companies which include opportunity assessment, revenue forecasting, pricing strategy, go-to-market strategy, strategic planning, project portfolio rationalization, and digital strategy

PA Consulting Group
2011 – 2017
Analyst to Principal Consultant, Life Sciences Strategy
Supported and led projects with global life sciences companies which include M&A opportunity assessment, customer engagement strategy, commercial operations reform and digital transformation while generating research and insights on technology in healthcare

Harvard-MIT Center for Engineering in Medicine
2009 – 2011
Applications Engineer
Designed and led the scale-up and testing of a range of 'lab on a chip' technologies that separate and capture specific cell sub-populations from blood with applications in oncology, infectious diseases and inflammation

PRO BONO ACTIVITIES

  • Development and launch support for medical practices (2022-2025)
  • Market assessment and business model development of at-home veterinary care (2018)
  • New market entry of existing motorcycle parts business in emerging markets (2016)
  • Development of a global health guidelines database for HIV-related skin disorders (2014)
  • New business models for in vitro diagnostics - NanoBioSym (2012)

SELECT PROJECTS

BUSINESS DEVELOPMENT
PROJECT
THERAPEUTIC AREA
Biologics Injectable Landscape Assessment and Strategy, Top 3 Global Pharma Company*
Inflammation
M&A Target Identification and Business Development Strategy, Fortune 50 Company*
Dermatology
Opportunity Assessment and Spin-off Strategy, Fortune 50 Company*
In-vitro Diagnostics
Opportunity Assessment and M&A Commercial Due Diligence, Drug Delivery Company*
Drug Delivery
Innovation Landscape and Assessment, Fortune 50 Company*
Dermatology
Opportunity Assessment and M&A Target Identification, Fortune 50 Company*
Sleep
COMMERCIAL STRATEGY
PROJECT
THERAPEUTIC AREA
Global Strategy Planning and Execution Roadmap, Fortune 50 Company*
Surgery
Strategic Planning and Project Portfolio Rationalization, Top 3 Global Diagnostics Company*
In-vitro Diagnostics
Global Strategy Roadmap and Execution Planning, Fortune 50 Company*
Infectious Diseases
Loss of Exclusivity Strategy Playbook and Authorized Generics Go-to-Market Planning
Neurology
Value-Based Care Strategy and Business Case, Top 3 Global Pharma Company
Cross-Portfolio
Digital Projects Portfolio Rationalization and Strategy Roadmap, Top 15 Global Pharma Company
Cross-Portfolio
Patient Support Programs Benchmarking and Roadmap, Fortune 50 Company
Cross-Portfolio
COMMERCIAL OPERATIONS
PROJECT
THERAPEUTIC AREA
Commercial Operating Model Transformation, Global Pharma Company
Neurology
Commercial Model Innovation and Implementation, Top 3 Global Pharma Company*
Cross-Portfolio
Digital Commercial Transformation, Top 5 Global Pharma Company*
Cross-Portfolio
Global Customer Interaction Management, Global Pharma Company*
Neurology
Commercial Compliance HCP Compensation Model Reformation, Top 3 Global Pharma Company
Cross-Portfolio
Digital Content Management Platform Assessment, Global Biotech Company
Cross-Portfolio
Patient Advocacy Outreach Operating Model and Roadmap, Top 15 Global Pharma Company*
Cross-Portfolio
CLINICAL DEVELOPMENT
PROJECT
THERAPEUTIC AREA
Clinical Quality and Compliance Sustainability Program, Top 5 Global Pharma Company
Cross-Portfolio
Program Management Competency Setup, Top 5 Global Pharma Company*
Vaccines
Managed Service for Clinical Document Development, Top 5 Global Pharma Company*
Cross-Portfolio
Restructuring Clinical Development SOPs, Top 10 Global Pharma Company
Cross-Portfolio
Developing Medical Device Labeling SOPs, Top 5 Global Pharma Company
Medical Devices
Automation Implementation for Clinical Development Projects, Fortune 50 Company
Cross-Portfolio
PRODUCT DEVELOPMENT
PROJECT
THERAPEUTIC AREA
Blood Imaging Analyzer Cost Optimization, Diagnostics Start-up
Hematology
Hemostatic Sponge Manufacturing Risk Assessment, Top 3 Global Pharma Company
Surgery
Testing and FDA Validation for Peripheral Stent, Medical Device Start-up
Cardiovascular
Point-of-care Diagnostics Microfluidic Device Development, Diagnostics Start-up
In-vitro Diagnostics
*Global Scope